Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

XBIT - XBiotech Inc.


IEX Last Trade
7.585
0   0%

Share volume: 41,274
Last Updated: Tue 24 Dec 2024 05:57:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.45%

PREVIOUS CLOSE
CHG
CHG%

$7.58
-3.22
0.74%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 0%
Dept financing 1%
Liquidity 75%
Performance 3%
Company vs Stock growth
vs
Performance
5 Days
-29.02%
1 Month
-34.40%
3 Months
-33.23%
6 Months
-0.88%
1 Year
14.80%
2 Year
48.51%
Key data
Stock price
$7.58
P/E Ratio 
-8.43
DAY RANGE
$4.37 - $4.57
EPS 
-$0.76
52 WEEK RANGE
$4.03 - $9.96
52 WEEK CHANGE
$14.50
MARKET CAP 
194.964 M
YIELD 
N/A
SHARES OUTSTANDING 
30.463 M
DIVIDEND
$2.0995
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$152,968
AVERAGE 30 VOLUME 
$93,875
Company detail
CEO: John Simard
Region: US
Website: xbiotech.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.

Recent news